Tlry Stock Quote: Comprehensive Financial Overview

Author

Reads 908

Stocks Overview on Smartphone with Stock Market Chart Background หุ้น หุ้นไทย ลงทุน เทรด
Credit: pexels.com, Stocks Overview on Smartphone with Stock Market Chart Background หุ้น หุ้นไทย ลงทุน เทรด

Tlry stock quote offers a comprehensive financial overview, providing investors with a detailed picture of the company's performance.

Tlry's revenue has been steadily increasing over the past few years, with a notable surge in 2022.

The company's net income has also seen a significant improvement, rising from a loss to a profit within a short period.

This financial growth can be attributed to the company's successful product launches and strategic partnerships.

For more insights, see: S B I Card Share Price

Financial Information

Tilray Brands's revenue in 2024 was $788.94 million, a 25.80% increase from the previous year. This significant growth is a positive sign for the company.

In terms of financial performance, Tilray Brands reported a loss of -$244.98 million in 2024, which is a significant improvement from the previous year's loss. The company's losses decreased by 83.14% in 2024 compared to 2023.

Here's a breakdown of Tilray Brands's income statements for 2024 and 2023:

Income Statements (USD)

Tilray Brands' income statements for the past few years show a significant increase in sales revenue. In 2024, the company's revenue was $788.94 million, a 25.80% increase from the previous year.

Credit: youtube.com, FINANCIAL STATEMENTS: all the basics in 8 MINS!

The company's sales have been steadily increasing over the years, with a notable jump from $166.98 million in 2019 to $788.94 million in 2024. This represents a 287.15% change.

Tilray Brands' gross profit on sales has also seen a significant improvement, increasing by 159.20% in 2024 compared to the previous year. This is a substantial increase from a loss of $35.10 million in 2019.

Here's a breakdown of the company's income statements in millions of USD:

The company's operating income has also seen a significant improvement, decreasing by 38.95% in 2024 compared to the previous year.

Dividend Calendar

Tilray (ex Aphria) has a history of not paying dividends, as seen in the dividend calendar.

The company has consistently paid a dividend of $0.00 since 2024, with no yield recorded.

You can see the dividend calendar below, which shows the dividend amount and yield for each year from 2017 to 2024.

Company Overview

Tilray Inc. is a pharmaceutical company that researches, cultivates, produces, and distributes medical and recreational cannabis and cannabinoids.

Credit: youtube.com, Tilray Brands (TLRY) Stock Price Update down (-2.77%) Today Still awaiting Marijuana regulatory.

It operates through two key divisions – Cannabis and Hemp – and runs a diversified portfolio of brands, including Canaca, Dubon, Yukon Rove, and Manitoba Harvest.

Tilray has a presence in numerous countries, including Argentina, Chile, Australia, New Zealand, Germany, Cyprus, Switzerland, the UK, Ireland, Portugal, and South Africa.

The company was founded in 2013 as a subsidiary of Privateer Holdings, a private equity firm that invests exclusively in the cannabis industry.

Tilray stock is listed on the Nasdaq Stock Market under the ticker symbol TLRY.

Tilray partnered with Sandoz, a subsidiary of Novartis, to co-brand and distribute non-smokable medical cannabis products in legal markets globally.

In 2019, Tilray acquired several companies, including Smith & Sinclair, FOUR20, Natura Naturals Holdings, and Manitoba Harvest.

Tilray announced a merger with Aphria to create the world's largest cannabis company by revenue, which would operate under Tilray's name and trade as TLRY.

Tilray became the first pure-play cannabis company to go public on a major US stock exchange, floating its shares on the Nasdaq exchange at a price of $17 per share.

If this caught your attention, see: Fifth Third Bank Stock Symbol

Stock Performance

Credit: youtube.com, TLRY Stock - Tilray Brands EARNINGS! CRASH to $1 or BOOM? - Martyn Lucas Investor

Tilray Brands's stock performance has been a topic of interest in recent times. The company's revenue increased by 25.80% in 2024 to $788.94 million, a significant growth from the previous year's $627.12 million.

The stock price has been on a rollercoaster ride, rising from $1.15 in December to $1.45 recently. However, this mini-rebound will be put to the test when the company publishes its financials.

Tilray Inc's market capitalization is approximately $1.027 billion, as of the latest data. The stock is listed on the NASDAQ exchange.

Here's a snapshot of the company's recent performance:

The company's diluted earnings per share (EPS) for the trailing 12 months is -$0.3, indicating a loss. The revenue growth year-over-year is 13.1%, while the earnings growth is 0%.

News and Events

Tilray, the pharmaceutical company that researches, cultivates, and distributes medical and recreational cannabis, has had its fair share of ups and downs. In 2018, the company went public on the Nasdaq exchange, floating its shares at $17 per share and gaining over 30% in its first day of trading.

Credit: youtube.com, TLRY Stock - Tilray Inc Stock Breaking News Today | TLRY Stock Price Prediction | TLRY

Tilray's stock price has been volatile, with a stellar rise to $300 per share in September 2018, followed by a downtrend that bottomed out at $2.43 in March 2020. The company's revenue has also been a concern, with several earnings reports showing a decline in revenue, including a Q4 2023 Earnings Release where the company reported a loss of $0.150 USD per share.

Tilray's financials have been a major concern, with the company reporting significant cash burn and revenue misses. The company's stock price has fallen over 10% after several earnings reports, raising concerns about the stock setting new lows.

Past Events

Tilray, formerly known as Aphria, has had a significant presence in the market with its annual general meetings and earnings reports. The company's financial performance has been a topic of interest for investors and analysts alike.

In 2023, Tilray's Annual General Meeting on November 21st resulted in a loss of $2.35 USD per share. This event marked a significant decline in the company's financial health.

Stock charts displays.
Credit: pexels.com, Stock charts displays.

Here are some key events from Tilray's past:

Tilray's Earnings Report for Q4 2023 resulted in a loss of $0.15 USD per share, while the Q3 2023 report showed a loss of $1.9 USD per share. These financial performances have been a subject of interest for investors and analysts.

Rating Downgrade

Tilray shares fell over 10% after another revenue miss and significant cash burn, raising concerns about the stock setting new lows.

The revenue miss and cash burn have investors worried about the company's financial stability. Tilray's overall financials remain a concern despite some growth in beverage revenues.

Investors are likely feeling frustrated with the company's inability to turn a profit. This is the latest setback for a company that has struggled to find its footing in the market.

The significant cash burn is a major red flag for investors, indicating that the company may not have the resources to sustain itself in the long term.

Cannabis Maker to Cut Drinks Lineup

Credit: youtube.com, CANNABIS EVENTS

Tilray, a pharmaceutical company that researches, cultivates, and distributes medical and recreational cannabis, has announced plans to cut its drinks lineup. This move comes after the company's revenue fell short of analyst estimates.

Tilray's revenue has been inconsistent, with some quarters showing growth and others missing estimates. In Q2 2024, the company's net revenue increased 9% year-over-year to $210.95 million, but still missed the consensus of $216.91 million.

Here's a breakdown of Tilray's past quarterly earnings reports:

Tilray's stock price has been affected by these revenue misses, with the company's shares falling over 10% after the Q2 earnings report. In 2023, the stock price was as low as $1.15 in December, but has since rebounded to around $1.45.

Tilray's plans to cut its drinks lineup may impact the company's revenue, but it's unclear how this will affect the stock price. The company's focus on cannabis and hemp products may lead to more consistent revenue growth in the future.

Frequently Asked Questions

Is Tilray stock expected to rise?

Yes, Tilray stock is expected to rise, with a 12-month average price target of $2.00 and 49.25% upside potential. Analysts have a Moderate Buy consensus rating, indicating a positive outlook for the stock.

What is the price target for TLRY in 2025?

The estimated price target for TLRY is between $1.70 and $4.00 USD, with a median estimate of $2.20 USD. Analysts' predictions suggest a potential price range for TLRY in 2025.

What is the symbol for Tilray?

The symbol for Tilray is TLRY, which is listed on the NASDAQ stock exchange.

Who owns the most Tilray shares?

The largest shareholders of Tilray include Morgan Stanley, Vanguard Group Inc, and BlackRock, Inc., among others. These institutional investors hold significant stakes in the company.

What is the price target for TLRY in 2024?

The price target for TLRY is forecasted to be between $1.75 and $4.00, with an average target representing an 83.57% potential upside from its current price of $1.43.

Harold Raynor

Writer

Harold Raynor is a seasoned writer with a keen eye for detail and a passion for sharing knowledge with others. With a background in business and finance, he brings a unique perspective to his writing, tackling complex topics with clarity and ease. Harold's writing portfolio spans a range of article categories, including angel investing, angel investors, and the Los Angeles venture capital scene.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.